tiprankstipranks
Advertisement
Advertisement

FDMT Stock Latest News

4D Molecular price target lowered to $23 from $45 at Evercore ISI
The Fly4D Molecular price target lowered to $23 from $45 at Evercore ISI
23d ago
FDMT
4D Molecular Therapeutics Consolidates Financial Leadership Under New Role
PremiumCompany Announcements
4D Molecular Therapeutics Consolidates Financial Leadership Under New Role
1M ago
8K
FDMT
4D Molecular assumed with a Buy at Jefferies
PremiumThe Fly
4D Molecular assumed with a Buy at Jefferies
1M ago
FDMT
Reimbursement and Pricing Pressures Threaten Commercial Outlook for 4D Molecular Therapeutics’ Gene Therapies
PremiumCompany Announcements
Reimbursement and Pricing Pressures Threaten Commercial Outlook for 4D Molecular Therapeutics’ Gene Therapies
2M ago
FDMT
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings Cheat Sheet
2M ago
FDMT
4D Molecular completes enrollment for 4FRONT-1 Phase 3 trial
PremiumThe Fly4D Molecular completes enrollment for 4FRONT-1 Phase 3 trial
3M ago
FDMT
4D Molecular assumed with an Overweight at Barclays
Premium
The Fly
4D Molecular assumed with an Overweight at Barclays
3M ago
FDMT
4D Molecular Therapeutics Restructures Equity via Warrant Exchange
Premium
Company Announcements
4D Molecular Therapeutics Restructures Equity via Warrant Exchange
3M ago
8K
FDMT
4D Molecular announces employment inducement grants
PremiumThe Fly
4D Molecular announces employment inducement grants
4M ago
FDMT
4D Molecular Therapeutics Expands Leadership With New Director Appointment
PremiumCompany Announcements
4D Molecular Therapeutics Expands Leadership With New Director Appointment
4M ago
8K
FDMT
4D Molecular Therapeutics: Encouraging Early CF Gene Therapy Signals Tempered by Limited Data, Supporting a Neutral Hold Rating
PremiumRatings
4D Molecular Therapeutics: Encouraging Early CF Gene Therapy Signals Tempered by Limited Data, Supporting a Neutral Hold Rating
5M ago
FDMT
4D Molecular announces interim data from 4D-710 Phase 1 AEROW trial
PremiumThe Fly
4D Molecular announces interim data from 4D-710 Phase 1 AEROW trial
5M ago
FDMT
4D Molecular Therapeutics Expands Phase 3 Trial Enrollment
PremiumCompany Announcements4D Molecular Therapeutics Expands Phase 3 Trial Enrollment
5M ago
8K
FDMT
4D Molecular Therapeutics Appoints New Chief Financial Officer
Premium
Company Announcements
4D Molecular Therapeutics Appoints New Chief Financial Officer
6M ago
8K
FDMT
4D Molecular names Kristian Humer as CFO
Premium
The Fly
4D Molecular names Kristian Humer as CFO
6M ago
FDMT
Promising Outlook for 4D Molecular Therapeutics: Buy Rating Backed by Strategic Partnerships and Strong Financial Position
PremiumRatings
Promising Outlook for 4D Molecular Therapeutics: Buy Rating Backed by Strategic Partnerships and Strong Financial Position
6M ago
FDMT
4D Molecular price target raised to $32 from $26 at RBC Capital
PremiumThe Fly
4D Molecular price target raised to $32 from $26 at RBC Capital
6M ago
FDMT
4D Molecular price target lowered to $33 from $38 at Barclays
PremiumThe Fly
4D Molecular price target lowered to $33 from $38 at Barclays
6M ago
FDMT
4D Molecular Therapeutics Reports Strategic Gains in Q3 2025
PremiumCompany Announcements
4D Molecular Therapeutics Reports Strategic Gains in Q3 2025
6M ago
FDMT
4D Molecular sees cash runway into 2H28
PremiumThe Fly4D Molecular sees cash runway into 2H28
6M ago
FDMT
4D Molecular reports Q3 EPS ($1.01), consensus (98c)
Premium
The Fly
4D Molecular reports Q3 EPS ($1.01), consensus (98c)
6M ago
FDMT
4D Molecular Therapeutics Closes $93.3 Million Stock Offering
Premium
Company Announcements
4D Molecular Therapeutics Closes $93.3 Million Stock Offering
6M ago
8K
FDMT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >